论文部分内容阅读
巴西圣保罗消息:Famotidine可能是治疗佐-埃二氏(Zollinger-Ellison)综合征的首选H_2受体拮抗剂。西部安大略大学内科教授John Howard在世界胃肠病学会议上称,一项研究证明,Famotidine比雷尼替丁(Ranitidine)药效强9倍,比甲腈咪胍(Cimitidine)强32倍。该药可以安全地治疗患促胃液素瘤的病人。这些病人如果不进行全胃切除术,根治产生促胃液素的肿瘤,几乎无例外地死于此综合征。 Famotidine在控制佐-埃二氏综合征病人胃酸分泌方面除了比甲腈咪胍或雷尼替丁强多倍外,也比多次、大剂量使用上述两药所产生的副作用要轻。在第Ⅰ期研究中,Howard等发现,9名病人控制胃酸分泌所需的Famoti-dine平均剂量仅为0.24g/天;而要达到相同的效果,雷尼替丁的平均需要剂量为2.1g/天,甲
Sao Paulo, Brazil - Famotidine may be the preferred H 2 receptor antagonist in the treatment of Zollinger-Ellison syndrome. John Howard, a professor of internal medicine at the University of Western Ontario, told the World Gastroenterology Conference that a study showed that Famotidine was 9 times more potent than Ranitidine and 32 times more potent than Cimitidine. This medicine safely treats patients with gastrinomas. Without total gastrectomy, these patients eradicated the gastrocinoid tumor almost without exception. Famotidine also has far fewer side effects than multiple, high doses of these two drugs in controlling gastric acid secretion in patients with Z-Ehls disease, in addition to many times more potent than cetmilellin or ranitidine. In the phase I study, Howard et al found that the average dose of Famoti-dine required for 9 patients to control gastric acid secretion was only 0.24 g / day; to achieve the same effect, the average required dose of ranitidine was 2.1 g / Day, A